# Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema

> **NCT05856331** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 99 (actual)

## Conditions studied

- Alpha 1-Antitrypsin Deficiency
- Emphysema

## Interventions

- **DRUG:** SAR447537
- **DRUG:** Zemaira

## Key facts

- **NCT ID:** NCT05856331
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-10-12
- **Primary completion:** 2025-08-06
- **Final completion:** 2025-08-06
- **Target enrollment:** 99 (ACTUAL)
- **Last updated:** 2025-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05856331

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05856331, "Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05856331. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*